the presence of significant RCA disease, but not stenting technique, are independent predictors of increased rates of CAE following LMCA PCI.
Background: Percutaneous coronary intervention (PCI) of complex true coronary bifurcation lesions is challenging and whether to use a dedicated side branch stent is still debatable. To date there is no published study evaluating the safety and efficacy of using an Everolimus-eluting stent (EES) in diabetic patients with true bifurcation lesions treated with dedicated 2-stent (2S) vs. a provisional 1-stent (1S) technique. We sought to compare outcomes with a dedicated 2S vs. provisional 1S strategy among diabetic patients undergoing bifurcation stenting using EES. Methods: We identified 202 diabetic patients with complex true bifurcation (Medina classification 1,1,1; 1,0,1; and 0,1,1) lesion who underwent bifurcation PCI using EES from February 2010 to December 2011. The PCI strategy was either a provisional 1S (n¼144) or dedicated 2S (n¼58) technique. Statistical analysis with all available follow-up data were constructed for time-to-event variables with Kaplan-Meier methodology and compared by log-rank test. Results: The baseline characteristics were well matched between two PCI strategies. In-hospital major adverse cardiac event (MACE) and postprocedure MI (CK-MB >3x Normal, 8.33% vs. 10.34%, P¼0.65). At 1-year follow-up, MACE tended to be lower for the 2S compared to the provisional 1S approach with the time to event analysis depicted in Figure 1 (P¼0.08).
Conclusions:
The conservative provisional 1S technique tended to have greater MACE events compared to the dedicated 2S technique in diabetic patients after treatment of complex true bifurcation lesions using newer generation EES.
TCT-415
Optimized Ghent University, Gent, Belgium Background: Main vessel stenting with final kissing balloon dilatation (FKBD) is widely employed, but many technical variations are possible that may affect the final result. In this study, two different FKBD strategies were investigated. Methods: Finite element simulations were used to virtually deploy and post-dilate three stent platforms within three bifurcation models, mimicking a range of coronary bifurcation anatomies. Stents were sized according to the distal branch diameter and deployed to a diameter of 3.2mm following the compliance charts. During a second step, a shorter (but larger) balloon was used to post-dilate the proximal stent segment. Two FKBD strategies were evaluated: "simultaneous FKBD" (n¼27) and "modified FKBD" (n¼27). In the simultaneous FKBD, both the side and main branch balloon were simultaneously inflated and deflated, with a maximal balloon pressure of 12atm. In the modified FKBD, the side branch balloon was inflated to a pressure of 12atm, and then deflated to 4atm. Subsequently, the main branch balloon was inflated to a pressure of 12atm. Eventually, both balloons were fully deflated. The following quantitative measures were used to compare both FKBD strategies: percentage of side branch obstruction, ellipticity index (the ratio of the maximal to the minimal diameter in the proximal stent segment) and percentage of malapposed struts (defined as strut-artery distance of more than 100 micron). The accuracy of the computer simulation results was evaluated by comparing the virtually predicted stent deformations with stent deformations observed during microCT visualised in-vitro bench testing. Results: Modified FKBD results in a lower ostial stenosis as compared to simultaneous FKBD (15AE9% vs. 20AE11%, p<0.001) and also reduces the elliptical stent deformation (ellipticity index ¼ 1.17AE0.05 vs. 1.36AE0.06, p<0.001). The amount of malapposed stent struts was not influenced by the FKBD technique (modified FKBD: 6.3AE3.6%, simultaneous FKBD: 6.4AE3.4%, p¼0.212). Conclusions: The modified FKBD procedure reduces the elliptical stent deformation and optimises the side branch access while avoiding stent distortion within the main vessel.
TCT-416
Impact Background: Scant data exist regarding the impact of diabetes mellitus (DM) status on percutaneous coronary intervention (PCI) for left main (LM) coronary artery disease. We sought to compare the impact of the presence of DM at baseline among pts undergoing LM PCI on long-term ischemic outcomes. Methods: Data from all consecutive patients from a single center were prospectively collected. Pts were stratified according to the presence or absence of DM at baseline. Coronary angiograms were analyzed by an independent angiographic core laboratory and all events adjudicated by an independent clinical events committee. Adverse ischemic outcomes were compared between the 2 groups up to 6-year follow-up. Results: Between Jan 2004 and Dec 2010, 1,528 consecutive pts underwent LM PCI. DM was present in 369 (24.1%) pts. Pts with DM were more likely to have increased weight, prior MI, hypertension, dyslipidemia and prior stroke. Angiographically, DM pts presented more frequently with 3-vessel-disease, 1,1,1 medina bifurcation and higher baseline SYNTAX score. Despite having more lesions treated and more stents implanted, DM pts had higher residual SYNTAX score after revascularization. One-year dual antiplatelet therapy compliance rates were high among the complete cohort (95.3%) and similar between both groups. At 6-year follow-up, no differences were seen in rates of all-cause death (6.0% vs. 4.7%, p¼0.36) and definite/probable stent thrombosis (ST; 1.6% vs. 1.7%, p¼0.90) between groups. However, DM pts had a higher rate of target lesion revascularization (TLR; 8.4% vs. 4.4%, p¼0.005), target vessel revascularization (TVR; 13.6% vs. 8.1%, p¼0.003), and stroke (4.9% vs. 1.3%; p¼0.002). By multivariate analysis, www.jacctctabstracts2013.com TUESDAY, OCTOBER, 29, 2013, 3:30 PM-5:30 PM DM was identified as a strong independent predictor of stroke (HR ¼3.09; 95% CI 1.52-6.29, p¼0.002), TLR (HR¼2.10; 95% CI 1.30-3.38, p¼0.002) and TVR (HR ¼1.66; 95% CI 1.15-2.39, p¼0.006). Conclusions: Among this large series of consecutives pts undergoing LM PCI, DM was not associated with an increase in death or ST, but was independently predictive of stroke, TVR and TLR at 6-year follow-up. Background: Patients with severe left ventricular (LV) dysfunction undergoing intervention (PCI) upon the unprotected left main coronary (ULM) or the last remaining conduit (LRC) are susceptible to peri-procedural heart failure or hypotension which may limit the effectiveness of revascularization efforts. Methods: The Protect II trial compared an LV assist device (Impella 2.5) to intraaortic balloon counterpulsation (IABP) in patients undergoing high risk coronary intervention. We analyzed 90 day outcomes from the subset of study subjects treated with ULM or LRC intervention. Results: A total of 448 patients were treated in the Protect II trial and of these 102 underwent ULM (34 Impella, 35 IABP) or another LRC (15 impella, 18 IABP) PCI per protocol definition. Of the ULM/LRC cohort (N¼ 102), 50% had class 3 or 4 heart failure, and the mean LVEF was 26%. Procedural differences between the two groups included a trend for more use of rotational atherectomy (RA), (22.4% vs 9.4%, p¼0.071) with Impella; when RA was used, patients on Impella were treated with longer atherectomy runs (94.1 vs 36.5 sec, p¼0.026). Duration of device support was much shorter (1.6 vs 10.8 hours, p¼0.013) with Impella compared to IABP. Comparing 90 day composite major adverse cardiac and cerebrovascular events (MACCE) of death, large myocardial infarction (MI) with CK-MB > 8x normal, stroke, or repeat revascularization procedures, Impella use was associated with less MACCE compared to IABP use (16.7% vs 34.0%; p¼0.047). The difference in MACCE was mainly driven by fewer strokes (0% vs 5.7%) and repeat procedures (0% vs 11.3%) with Impella. Conclusions: In this subgroup analysis of a randomized trial, in patients with severe LV dysfunction undergoing PCI to the ULM or LRC, the use of Impella LV assist during intervention was associated with a lower risk of major adverse events at 90 days compared to the use of a IABP. Background: Recently, the SYNTAX score-2 (SxS-2) was developed in an attempt to individualize and help the decision-making process between percutaneous coronary intervention (PCI) and coronary artery bypass graft (CABG) in the management of complex coronary artery disease (CAD). We sought to evaluate and confirm the prognostic capacity of the SxS-2 among a group of 1,528 consecutive patients who already underwent left main (LM) PCI. Methods: Data from all consecutive patients from a single center undergoing LM PCI were prospectively collected. Coronary angiograms and the resulting SYNTAX scores (SxS)/residual SxS were assessed by an independent angiographic core laboratory, and then the SxS-II derived for both PCI and CABG using patients' baseline clinical characteristics. Patients were divided and compared according to whether the SxS-II indicated PCI vs. CABG as the most favorable strategy of revascularization. Cumulative adverse ischemic outcomes, including death, were compared between the 2 groups. Results: Among the study population of 1528 patients, 238 patients (15.6%) were deemed to be better candidates for CABG. Baseline and residual SxS were higher in CABG group compared with the PCI group (26.3AE8.1 vs. 23.5AE6.8, p<0.0001 and 6.0AE7.4 vs. 4.1AE5.5, p¼0.0001, respectively). At a mean follow-up of 4.4 years, the CABG group had a non-significant trend toward higher death (6.7% vs. 4.7%, p¼0.21), mainly driven by cardiac death (5.0% vs. 2.7%, p¼0.07), and increased myocardial infarction (11.3% vs. 6.8%, p¼0.02). Multivariate analysis showed CABG preference based on SxS-II to be an independent predictor of mortality (HR¼4.13; [95% CI] [1.59, 10.7] p¼0.004) after LM PCI. Conclusions: Results from this large series of consecutive patients who underwent LM PCI retrospectively confirmed the prognostic capability of the SxS-II for mortality among patients with complex coronary artery disease.
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Side branch patency after implantation of the novel DESolve bioresorbable vascular scaffold system in the treatment of de novo coronary lesions Background: Background: The DESolveÒ novolimus-eluting bioresorbable scaffold system (Elixir Medical Co., Sunnyvale, CA) is a novel bioresorbable vascular scaffold device that combines a PLLA-based scaffold (strut thickness 150 mm) coated with a potent antiproliferative sirolimus metabolite -Novolimus (5 mm per mm of scaffold length). Our aim was to investigate the occurrence of side branch (SB) compromise after implantation of the DESolve device in single de novo coronary lesions Methods: Methods: 126 patients/lesions were prospectively enrolled in the multicenter (13 sites), non-randomized, single-arm DESolve Nx trial. Lesion criteria were < 14 mm in length located in a native coronary vessel measuring 2.75-3.5 mm in diameter. SB compromise, defined as vessel occlusion (TIMI flow 0/1) at postprocedure, was evaluated within the treated segment covered by the study device at an independent angiographic core laboratory. All SBs >1.0 mm in diameter (by visual estimation) were considered for analysis. Results: Results: Overall, there were 71 SBs >1.0 mm found in 123 coronary segments treated by 126 scaffolds (3 lesions did not receive the study device; 3 lesions received 2 study devices). The majority of SBs (96%) had pre-procedure TIMI 3 flow. During the procedure, neither guide wire protection nor intervention was performed in any SB. At post-procedure, SB occlusion was detected in only 3 cases, representing a 4.2% SB compromise rate. Importantly, there were no adverse clinical events during hospitalization associated with SB occlusion. Conclusions: Conclusions: In the prospective, non-randomized, single-arm, multicenter DESolve Nx trial, SB compromise -as determined by vessel occlusion after implantation of the novel DESolve bioresorbable vascular scaffold, was relatively low (4.2%) and was not associated with adverse clinical events during index hospitalization. Results: Second-generation DES use in this setting was associated with less major adverse cardiac events (MACE) (23.1% vs. 14.4%, p¼ 0.02) as well as lower target vessel revascularization (TVR) rates (15.5% vs. 8.3%, p¼0.01) at 2-year follow-up. Target lesion revascularization, both per patient (12.6% vs. 7.4%, p¼0.02) and per bifurcation (11.8% vs. 7.0%, p¼0.03), was also improved with second-generation DES over the same follow-up period. Propensity-score adjusted analysis suggested than first-generation DES was an independent predictor of both MACE (HR, 0.53; 95% CI, 0.33-0.85; p¼0.01) and TVR (HR, 0.44; 95% CI, p¼0.01) . Conclusions: Our results suggest that the use of second-generation DES for the treatment of bifurcation lesions is associated with better clinical outcomes as compared to first-generation DES, largely due to a lower need for repeat revascularization. TUESDAY, OCTOBER, 29, 2013, 3:30 PM-5:30 PM www.jacctctabstracts2013.com B130 JACC Vol 62/18/Suppl B j October 27-November 1, 2013 j TCT Abstracts/POSTER/Bifurcation and Left Main Interventions
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